In vivo (31)P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial Journal Article
| Authors: | Arias-Mendoza, F.; Payne, G. S.; Zakian, K. L.; Schwarz, A. J.; Stubbs, M.; Stoyanova, R.; Ballon, D.; Howe, F. A.; Koutcher, J. A.; Leach, M. O.; Griffiths, J. R.; Heerschap, A.; Glickson, J. D.; Nelson, S. J.; Evelhoch, J. L.; Charles, H. C.; Brown, T. R.; Cruz-Lobo, J.; Murphy-Boesch, J.; Negendank, W. G.; Shukla-Dave, A.; Oregioni, A.; Collins, D. J.; Maisey, N. R.; Ronen, S.; Doyle, V. L.; Rijpkema, M.; Poptani, H.; Lenkinski, R. E.; Vigneron, D. B.; Hu, J. |
| Article Title: | In vivo (31)P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial |
| Abstract: | The standardization and reproducibility of techniques required to acquire anatomically localized 31p MR spectra non-invasively while studying tumors in cancer patients in a multi-institutional group at 1.5 Tare reported. This initial group of patients was studied from 1995 to 2000 to test the feasibility of acquiring in vivo localized 31P MRS in clinical MR spectrometers. The cancers tested were non-Hodgkin's lymphomas, sarcomas of soft tissue and bone, breast carcinomas and head and neck carcinomas. The best accrual and spectral quality were achieved with the non-Hodgkin's lymphomas. The initial analysis of the spectral values of the sum of phosphoethanolamine plus phosphocholine normalized by the content of nucleotide triphosphates in a homogeneous sample of 32 NHL patients studied by in vivo 31P MRS showed good reproducibility among different institutions. No statistical differences were found between the institution with the largest number of cases accrued and the rest of the multi-institutional NHL data (2.2 ± 0.64, mean ± standard error; n = 17, vs 2.08 ± 0.14, n = 15). The preliminary data reported demonstrate that the institutions involved in this trial are obtaining reproducible 31P MR spectroscopic data non-invasively from human tumors. This is a fundamental prerequisite for the international cooperative group to be able to demonstrate the clinical value of the normalized determination of phosphoethanolamine plus phosphocholine by 31P MRS as predictor for treatment response in cancer patients. Copyright © 2006 John Wiley & Sons, Ltd. |
| Keywords: | osteosarcoma; controlled study; treatment outcome; major clinical study; clinical trial; cancer patient; nuclear magnetic resonance imaging; reproducibility; tumor localization; controlled clinical trial; image analysis; oncology; information processing; prediction; pathological anatomy; standardization; nonhodgkin lymphoma; feasibility study; statistical analysis; tumors; image quality; multicenter study; breast carcinoma; bone; soft tissue sarcoma; magnetic resonance spectroscopy; malignant neoplastic disease; patient treatment; phosphorus nuclear magnetic resonance; non invasive measurement; image display; analytical error; head and neck carcinoma; tissue; proton nuclear magnetic resonance; international cooperation; sample size; nucleotide; phosphoethanolamine; phosphorus 31; phosphorylcholine; localized; spectrum analysis; non-invasive; phosphocholine; breast carcinomas; head and neck carcinomas; 31 p mr spectroscopy; multi-institutional group; non-hodgkin's lymphomas; sarcomas of soft tissue and bone; multi-institutional trial; nucleotide triphosphates; phospoethanolamine; vicia sativa |
| Journal Title: | NMR in Biomedicine |
| Volume: | 19 |
| Issue: | 4 |
| ISSN: | 0952-3480 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2006-06-01 |
| Start Page: | 504 |
| End Page: | 512 |
| Language: | English |
| DOI: | 10.1002/nbm.1057 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 19" - "Export Date: 4 June 2012" - "CODEN: NMRBE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work